Preclinical Patient-Derived Modeling of Castration-Resistant Prostate Cancer Facilitates Individualized Assessment of Homologous Recombination Repair Deficient Disease

In vitro, castration-resistant prostate cancer (LNCaP) sublines revealed a homologous recombination repair defect and enhanced sensitivity to olaparib and cisplatin due to impaired RAD51 expression and recruitment.